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Elevated Low Density Lipoprotein Receptor Activity in Leukemic
Cells With Monocytic Differentiation
By Sigurd Vitols, G#{246}sta Gahrton, Ake Ost, and Curt Peterson
The receptor-mediated degradation of 12￿1-low density lipo-
protein (LDL) was compared in normal white blood cells
and leukemic cells. The cells were isolated from the
peripheral blood and bone marrow of healthy subjects and
patients with newly diagnosed leukemia. The cells from
most of the 40 consecutive patients with acute
myelogenous leukemia showed markedly higher degrada-
tion rates as compared to mononuclear cells and granulo-
cytes from peripheral blood and nucleated cells from the
bone marrow of healthy individuals. Leukemic cells from
patients with monocytic (FAB-M5) or myelomonocytic leu-
kemia (FAB-M4) exhibited the highest degradation rates.
The rate of receptor-mediated degradation of 125l-LDL was
also high in leukemic cells from all three patients with
L OW DENSITY LIPOPROTEIN (LDL) is the
major cholesterol-carrying lipoprotein in human
plasma. The LDL particles contain a lipid core of
about I ,500 cholesteryl ester molecules surrounded by
a polar shell of free cholesterol, phospholipids, and
protein.’ In recent years, it has been shown that human
cells express cell surface receptors for LDL.’￿3 Evi-
dence has been presented that, after binding to the
receptor, LDL is internalized and degraded, presum-
ably in lysosomes.’4 The lipid core of LDL yields
unesterified cholesterol, which is used for membrane
synthesis, whereas the protein part of LDL is degraded
to amino acids, as outlined by Goldstein et al.’￿ Recent
studies on a few patients with acute myebogenous
leukemia (AML) indicate that freshly isolated leu-
kemic cells from peripheral blood have higher LDL
receptor activities than normal mononuclear cells.5
In the present study, we have determined the rate of
receptor-mediated degradation of ‘25l-LDL by freshly
isolated leukemic cells from peripheral blood and bone
marrow of patients with AML, acute lymphoblastic
leukemia (ALL), acute undifferentiated leukemia
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chronic myelogenous leukemia in blast crisis. as well as in
two of three patients with acute undifferentiated leukemia.
In contrast. leukemic cells isolated from two patients with
acute lymphoblastic leukemia showed low rates. In most
cases. there was little difference in LDL receptor activity
between leukemic cells isolated from peripheral blood and
those from bone marrow. Hypocholesterolemia was a
frequent finding in the leukemic patients. There was an
inverse correlation between the plasma cholesterol level
and the rate of receptor-mediated degradation of 126l-LDL
by the leukemic cells. Studies are now in progress to
investigate the possibilities of using LDL as a carrier of
cytotoxic drugs in the treatment of leukemia.
(AUL), and chronic myelogenous leukemia (CML) in
blast crisis. We have also studied the receptor-
mediated degradation in granulocytes and mononu-
clear cells from peripheral blood and in nucleated bone
marrow cells from healthy subjects. Moreover, we have
correlated the LDL receptor activities of the leukemic
cells from the 40 AML patients to the leukemic
subclasses according to the FAB system.6 A prelimi-
nary report of the present studies has been presented
earlier.7
Materials
MATERIALS AND METHODS
Sodium iodide 125 (carrier-free, pH 7- 11) was purchased from
the Radiochemical Centre, Amersham, U.K. Sodium metrizoatc/
Ficoll (Lymphoprep) was obtained from Nyegaard and Co., Oslo,
Norway, and Dextran T 500 and I 200 and Sephadex gel filtration
columns (PDIO) from Pharmacia Fine Chemicals, Uppsala, Swe-
den. Plastic tissue culture dishes (35 x 10 mm) were obtained from
Becton Dickinson and Co., Oxnard, CA, and tissue culture medium
RPMI 1640 from Gibco-Biocult Ltd., Paisley, Scotland.
Patients
Table I summarizes the clinical and hematologic data on the
patients studied. Nineteen of the AM L patients were females, with a
mean age of65 yr (range 28-88). The mean age ofthe 21 male AM L
patients was 60 yr (range 22-79).
Four of the 5 patients with ALL/AUL were females and one was
male; their mean age was 43 yr. Three CML patients in blast crisis
were studied, I male and 2 females; their mean age was 67 yr.
Lipoproteins
Human LDL (density 1.019-1.063 g/ml) was isolated by ultra-
centrifugation of serum from healthy blood donors on a sodium
chloride gradient.8 Lipoprotein-deficient serum (LPDS) with a
density > I .21 g/ml was prepared from serum from healthy blood
donors. After adjusting the density to 1.21 g/ml by the addition of
sodium bromide, the serum was submitted to ultracentrifugation in a
Beckman 50 Ti rotor at 50,000 rpm for 20 hr at 10#{176}C. The top
fraction (containing the lipoproteins) was removed, and the bottom
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Table 1 . Summary of Clinical and Hematologic Data
Leukemic Cells (%)
Subject Age/Sex WBC (x 1O’/Liter) PB BM Diagnosis/FAB Subclass
1 66/F 14.5 50 80 CMML. blast crisis/M4
2 67/F 150.0 88 80 AML/M5B
3 22/F 148.0 92 95 ALL/L2
4 32/F 17.2 70 90 ALL/L2
5 28/F 1.7 92 74 AML/M2
6 65/F 30.3 64 92 AML/M3
7 45/F 379.0 92 93 AML/M1
8 45/M 23.8 88 79 AML/M4
9 67/M 14.1 60 65 AML/M5B
10 73/M 0.5 74 62 AML/M2
11 67/F 73.4 21 50 AML/M2
12 63/M 39.0 32 63 CML, blast crisis/M2
13 79/M 18.5 76 88 AML/M2
14 88/F 0.8 68 62 AML/M2
15 55/M 13.9 50 52 AML/M4
16 46/F 10.0 84 95 AUL
17 76/F 1.1 14 65 AML/M1
18 59/F 130.0 62 91 AML/M4
19 77/M 9.2 63 75 AML/M2
20 72/F 56.4 56 50 CML. blast crisis/M2
21 74/F 15.0 94 95 AML/M3
22 55/F 54.0 74 90 AML/M2
23 75/M 59.4 99 96 AUL
24 55/M 59.8 45 64 AML/M4
25 76/M 7.4 56 82 AML/M4
26 66/M 1.3 20 69 AML/M2
27 22/M 60.0 82 87 AML/M2
28 77/M 150.0 88 92 AML/M2
29 61/M 1.5 62 70 AML/M2
30 59/F 4.0 68 84 AML/M1
31 71/M 41.9 50 73 AML/M4
32 39/M 22.0 90 86 AML/M4
33 60/F 12.6 90 95 AML/M1
34 74/F 130.0 83 90 AML/M4
35 39/M 15.5 48 90 AML/M2
36 75/F 195.0 79 90 AML/M5B
37 59/M 132.0 63 95 AML/M5B
38 76/F 21.2 35 74 AML/M4
39 73/M 21.0 89 #{149} 81 AML/M2
40 39/M 1.5 32 78 AML/M1
41 70/M 23.8 73 75 AML/M2
42 41/F 23.4 49 91 AUL
43 78/F 8.0 64 76 AML/M4
44 71/M 14.0 52 57 AML/M2
45 77/F 12.6 22 64 AML/M5B
46 27/F Healthy volunteer Cells isolated by dextran sedimentation
47(a) 36/F Bone marrow donor Cells isolated by dextran sedimentation
47(b) 36/F Bone marrow donor Cells isolated on Lymphoprep
48 27/F Bone marrow donor Cells isolated on Lymphoprep
49 49/M 60.0 90 95 AML/M5B
50 66/F 35.9 75 72 AML/M4
51 54/F 144.0 71 84 AML/M4
WBC, white blood cell count; PB. peripheral blood; BM, bone marrow; CMML. chronic myelomonocytic leukemia; leukemic cells - blast cells +
promyelocytes/promonocytes.
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fraction was recentrifuged. The lipoprotein-deficient fractions were
then pooled, dialyzed extensively against phosphate-buffered saline,
pH 7.4, and finally heat inactivated by incubation at 56#{176}C for 30
mm. LDL was labeled with 1251 to a specific activity of 250-900
cpm/ng, as described by Langer et al.9 The reaction mixture was
passed through a Sephadex G25 column (PD1O) and dialyzed
extensively against 0.1 5 M NaCI containing 0.3 mM EDTA to
remove free iodide. The preparation was filtered through a 0.45-zm
Millipore filter (Millipore Corp., Bedford MA), stored at 4#{176}C, and
used within 4 wk. The amount of free iodide was less than 1% of the
total radioactivity in the final preparation. The purity of the LDL
and LPDS preparations was checked by agarose gel electrophoresis.
LDL was quantitated as protein by the Lowry assay,’#{176} using bovine
serum albumin as standard. Reductive methylation of LDL was
carried out as described by Wiesgraber et al”
Isolation ofLeukemic Cells From Blood and Bone
Marrow
Peripheral blood and bone marrow samples were obtained at the
time of diagnosis from the same blood and bone marrow specimens
as were used for routine clinical morphological and cytochemical
examinations. At that time, the patients with acute leukemia had not
received any cytotoxic treatment.
Leukemic cells were isolated from heparinized peripheral blood
by centrifugation on Lymphoprep (density 1.077 g/ml).’2 More than
95% of the cells obtained were viable, as determined by the trypan
blue exclusion test. The yield of leukemic cells was 90%-95% of
those originally present in the blood sample. The cell suspensions
isolated from peripheral blood by this technique contained a mixture
of immature cells (blast cells, promyelocytes, promonocytes) and
mature cells (lymphocytes and monocytes) in the same proportions
as they occurred in the blood smears.
Leukemic cells in bone marrow aspiration biopsies from the
sternum or the iliac crest were isolated from heparinized specimens
diluted with an equal volume of tissue culture medium by centrifuga-
tion on Lymphoprep, as described above. The suspensions obtained
contained the same kind of immature and mature mononuclear cells
as described for peripheral blood, and in addition, a small percentage
of red cell precursors.
Isolation ofNormal Blood and Bone Marrow Cells
Mononuclear cells were isolated from heparinized peripheral
blood samples from adult blood donors at the Karolinska Hospital,
Stockholm, by the same technique as was used for the isolation of
leukemic cells from peripheral blood. The isolated cell suspensions
contained approximately 85% lymphocytes, 10% monocytes, and 5%
granulocytes.
Granulocytes were isolated from the blood samples after first
removing the mononuclear cells as described above. Remnants of
Lymphoprep were carefully removed, and the resulting pellet from 3
ml of peripheral blood, containing granulocytes and red blood cells,
was diluted with 1 ml of plasma from the same subject and 0.4 ml of
4.5% (w/v) dextran T 200 containing 100 IU of heparin. The
mixture was allowed to sediment at 4#{176}C and, after 40 mm, the buffy
coat was collected and the cells washed by low speed centrifugation.
The suspensions obtained contained 90%-95% granulocytes, with a
yield of about 60% and a viability of 95%, as determined by the
trypan blue exclusion test.
Heparinized bone marrow specimens (iliac crest aspirates diluted
with tissue culture medium) were obtained from donors of bone
marrow grafts. Nucleated cells were isolated by diluting the bone
marrow suspension with an equal volume of 2% (w/v) dextran T 500
in 0.9% sodium chloride containing 33 lU heparin/mI and leaving
the mixture at room temperature for 40 mm to allow the red cells to
sediment. The buffy coat formed was collected, and the cells were
washed by low speed centrifugation.
Mononuclear cells from bone marrow were isolated by centrifuga-
tion on Lymphoprep as described for peripheral blood. The sus-
pensions obtained contained 60%-70% lymphocytes, 5%-l0%
monocytes, I 5%-20% red cell precursors, and 5% granulocytic
precursors.
Cellular Degradation of’251-LDL
The isolated cells (3 x 106) were incubated for 4-6 hr with
‘251-LDL in I ml of RPMI 1640 supplemented with L-glutamine,
30% LPDS, and antibiotics (100 lU penicillin plus 100 ￿g strepto-
mycin/mI medium). All incubations were performed in 35 x 10 mm
tissue culture dishes at 37#{176}C in humidified air containing 5% CO2.
The incubations were terminated by separating the cells from the
medium by low speed centrifugation at 4#{176}C for 5 mm.
Blank incubations were performed under identical conditions, but
in the absence of cells. The degradation of ‘251-LDL was determined
from the appearance of noniodide trichloroacetic acid (TCA) soluble
material in the incubation medium, as described by Goldstein et al.2
In brief, undegraded, high molecular weight ‘251-LDL in the medium
was precipitated with TCA. After centrifugation, free iodide was
separated from degradation fragments of ‘25l-LDL in the superna-
tant by oxidation with H202 and extraction with chloroform. An
aliquot of the aqueous phase was then assayed for radioactivity to
determine the degradation of ‘25l-LDL.
Morphologic and Cytochemical Diagnosis
of Leukemia
Our criteria for the diagnosis of acute leukemia have been
described previously.’3 The acute leukemias were classified accord-
ing to the FAB system,6 with minor modifications as reported
previously.’4 Leukemias with a negative cytochemical profile and
without immunologic B and T cell markers, as well as a negative
reaction for common ALL antigen (CALLA) were classified as
acute undifferentiated leukemia (AUL). The cytochemical staining
techniques used for classification have been presented earlier.’4
Analysis ofPlasma Cholesterol
Total plasma cholesterol concentrations were determined in blood
samples obtained at the time ofdiagnosis by an enzymatic method-
Nycotest (Nyegaard & Co., Oslo, Norway).
RESULTS
The degradation of ‘25I-LDL by beukemic cells iso-
bated from the peripheral blood of an AML patient
(no. 50) as a function of the incubation concentration
of ‘251-LDL is shown in Fig. 1 . At concentrations below
50 ￿g/ml, the degradation rose sharply with increasing
concentration. Further increase in the concentration of
‘25ILDL led to a considerably less steep increase in the
degradation rate, which was linear above 75 ￿g/ml. In
the presence of a 20-fold excess of unlabeled LDL, the
degradation of ‘25I-LDL was markedly inhibited. ln
this case, the degradation increased linearly with the
concentration of ‘251-LDL over the whole concentra-
tion range studied. The slope of this curve was similar
to that of the terminal linear part of the degradation
curve obtained in the absence of unlabeled LDL. By
subtracting the values for degradation of ‘251-LDL in
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Fig. 2. Degradation of 121l-LDL by leukemic cells isolated from
the bone marrow of patient no. 19 as a function of the concentra-
tion of ‘2’1-LDL in the medium (filled circles) and the high affinity
component (open circles) of the ‘2l-LDL degradation calculated by
substracting the amounts contributed by the low affinity process.
as described in the text. The incubation time was 6 hr. Each point
shows the mean result for duplicate incubations.
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Fig. 1. Degradation of ‘2￿l-LDL in the presence (open circles)
and absence (filled circles) of a 20-fold excess of unlabeled LDL by
leukemic cells isolated from the peripheral blood of patient no. 50
as a function of the concentration of ‘2￿l-LDL in the medium. The
incubation time was 6 hr. Each point shows the mean result for
duplicate incubations.
the presence of unlabeled LDL from the degradation
values in its absence, a saturable curve was obtained
with a maximal velocity at 50-60 ￿sg/ml (not shown).
In Fig. 2, similar data are presented for beukemic cells
isolated from the bone marrow of another AML
patient (no. 19). The high affinity component of the
‘25ILDL degradation was calculated by subtracting,
from the degradation values obtained, the amounts
contributed by the low affinity process, as estimated by
extrapolating the slope of the linear terminal part of
the degradation curve. Here again, saturation of the
high affinity process was observed at an incubation
concentration of 50-60 ￿ig/ml. Similar saturation
kinetics were obtained when studying isolated leu-
kemic cells from other patients, as well as when
studying isolated mononuclear cells, polymorphonu-
clear cells, and nucleated bone marrow cells from
healthy subjects.
The effects of unlabeled native and methylated LDL
on the degradation of ‘25I-LDL (25 ￿zg/ml) by leu-
kemic cells isolated from the peripheral blood of an
AML patient (no. 49) are shown in Fig. 3. Native
LDL, but not methylated LDL, inhibited the degrada-
tion of ‘251-LDL by the leukemic cells.
A comparison of the high affinity degradation rates
of various types of normal and leukemic cells isolated
from peripheral blood and bone marrow is shown in
Fig. 4. High affinity degradation of ‘25I-LDL at a
concentration of 25 zg/ml was calculated by subtract-
. I’S
ing the amount of l-LDL degraded in the presence of
a 20-fold excess of unlabeled LDL (nonspecific degra-
dation) from the amount of ‘251-LDL degraded in the
absence of unlabeled LDL (total degradation). The
high affinity degradation always exceeded 80% of the
total degradation of ‘251-LDL.
The mean high affinity degradation rates for granu-
locytes and mononuclear cells isolated from peripheral
blood and for nucleated cells from the bone marrow of
healthy individuals were 0.40 ng/hr/l06 cells (range
0.28-0.54), 0.46 ng/hr/106 cells (range 0.24-0.54),
and 0.49 ng/hr/l06 cells (range 0.30-0.60), respec-
tively.
In 2 of 5 patients with ALL/AUL, the high affinity
degradation rate of ‘25l-LDL for leukemic cells from
peripheral blood was elevated (0.90 and 2.25 ng/
hr/106 cells). The leukemia of both these patients was
classified as AUL.
In all three CML patients in blast crisis (nos. 1, 12,
and 20), leukemic cells isolated from peripheral blood
exhibited high degradation rates-l4.0, 2.45, and I .86
ng/hr/106 cells, respectively. No. I, who had the
￿o 200 300 400 5￿
COMPETING UPOPROTEIN (pg/mI)
Fig. 3. Effect of native LDL (filled circles) and methylated LDL
(open circles) on the degradation of ‘25l-LDL (25 ￿g/ml) by isolated
leukemic cells from peripheral blood from patient no. 49. The
incubation time was 6 hr. Each point shows the mean of duplicate
incubations.
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Fig. 4. High affinity degradation of ‘25l-LDL by normal white
blood cells and leukemic cells. PB. cells isolated from peripheral
blood; BM. cells isolated from bone marrow; MN. mononuclear
cells; GR, granulocytes. The cells were incubated with 25 pg/mI of
‘2￿l-LDL in the presence and absence of 500 ig/ml of unlabeled
IDI for 4-6 hr. and the high affinity degradation rate was
calculated as described in the text. Each point shows the mean for
duplicate incubations. The numbers refer to subjects in Table 1.
highest value, was a patient with a blastic transforma-
tion classified as acute myelomonocytic leukemia
(M4).
Leukemic cells from peripheral blood and bone
marrow from most of the 40 patients with AML had
markedly elevated high affinity degradation rates of
‘251-LDL, although there were 6 patients with degra-
dation rates in the range seen in cells isolated from
healthy subjects and another 7 patients who had only
slightly elevated values (0.70-0.95 ng/hr/b06 cells).
The cells from all other AML patients had degradation
rates that were 2-30 times higher than those of the
normal cells.
Figure 5 shows the high affinity degradation rates
for leukemic cells from peripheral blood and bone
marrow from the AML patients in relation to their
leukemic subclasses according to the FAB classifica-
tion. The cells from 5 patients with myeboblastic
leukemia without maturation (Ml) all showed rela-
tively low rates: means of 0.62 (range 0.38-0.88) and
0.81 (range 0.15-1.90) ng/hr/106 cells for cells from
peripheral blood and bone marrow, respectively. The
leukemia of I 5 patients was classified as myeloblastic
leukemia with maturation (M2). The mean degrada-
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Fig. 5. Rate of high affinity degradation of ‘25l-LDL by AMI
cells isolated from peripheral blood and bone marrow in relation to
the FAB subclasses of AMI. Abbreviations as in Fig. 4.
tion rates for the cells from these patients were I .57
(range 0.40-4.10) and 1.56 (range 0.25-3.78) ng/
hr/ I 06 cells for cells from peripheral blood and bone
marrow, respectively.
Two of the AML-patients had a hypergranular
promyelocytic leukemia (M3), and their cells had
relatively low degradation rates.
The leukemia of I 2 patients was classified as acute
myelomonocytic leukemia (M4). The cells from all but
two of these patients had very high degradation rates.
The mean values were 2.29 (range 0.53-8.72) and 5.18
(range 0.80-1 1.0) ng/hr/l06 cells for leukemic cells
from peripheral blood and bone marrow, respectively.
Six patients were classified as having acute mono-
cytic leukemia with maturation (M5B). The beukemic
cells from all of these patients had degradation rates
that were several times higher than that of normal
white blood cells. The mean value for leukemic cells
from peripheral blood of the MS group was 6.36 (range
1.70-12.78) and for cells from bone marrow 8.87
(range 3.40-14.90) ng/hr/106 cells. The highest deg-
radation rate in the present study was found in patient
no. 36, a 75-yr-old woman with a leukemia classified as
M5B. She had a peripheral blast cell count of 150 x
109/liter, 90% leukemic bone marrow infiltration and a
degradation rate of 14.90 ng/hr/l06 cells (bone mar-
row).
No patient in the present study had a leukemia
classified as M5A or M6.
In some of the patients, the ‘251-LDL degradation
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Fig. 6. Total plasma cholesterol concentrations in patients
with AMI in relation to the rate of high affinity degradation of
‘￿‘l-LDL by the leukemic cells isolated from peripheral blood. The
numbers refer to subjects in Table 1 . The regression line was
calculated according to the method of least squares.
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rate differed markedly between cells isolated from
peripheral blood and from bone marrow. In most of
these cases (e.g. patients I 8, 24, 34, 36), the degrada-
tion rate was higher in the cells isolated from bone
marrow, but occasionally, the reverse was found.
In this study, the rates of degradation of 251-LDL
are expressed per I 06 cells. The relative differences
between normal cells and leukemic cells and between
different subgroups of AML were not due to differ-
ences in cell size as estimated from the cellular protein
content.
Total plasma cholesterol concentrations were deter-
mined in 28 of the patients with AML. The mean (±
SD) cholesterol concentration was 3.3 ± 1.0 mmole/
liter. Figure 6 shows the cholesterol levels of the
patients in relation to the rate of high affinity degrada-
tion of ‘25I-LDL by leukemic cells isolated from
peripheral blood. Regression analysis showed that the
high affinity degradation rate by the leukemic cells
was negatively correlated to the patients’ plasma cho-
lesterol concentrations, (r = -0.48, p = 0.01).
DISCUSSION
The data in this study provide evidence that isolated
leukemic cells from the peripheral blood and bone
marrow of AML patients degrade ‘251-LDL by a
saturable high affinity process with a maximal velocity
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at about 50-60 ￿zg/ml. This process is considered to be
the result of binding of LDL to cell surface receptors
followed by internalization and degradation of LDL in
lysosomes.’5 In the presence of a large excess of
unlabeled LDL, the degradation of 251-LDL was
strongly inhibited. The degradation of ‘251-LDL in that
situation probably represents nonspecific degradation
due to bulk fluid endocytosis, as demonstrated by
Goldstein et al.2 The saturation curves obtained in our
study are similar to those of Ho et al. for normal
mononuclear and leukemic cells isolated from periph-
eral blood.35 The specificity of the assay is further
supported by the fact that native LDL, but not methyl-
ated LDL, which does not bind to the LDL receptor,”
inhibited the degradation of ‘25I-LDL by leukemic
cells.
In the present study, we have compared the recep-
tor-mediated degradation of ‘25I-LDL by normal and
leukemic cells isolated from peripheral blood and bone
marrow. Freshly isolated normal mononuclear cells
exhibited a low rate of LDL degradation that was very
similar to that reported by Ho et al.35 Our results show
that granulocytes isolated from peripheral blood and
nucleated cells from normal bone marrow also express
low LDL receptor activities.
We have found that leukemic cells isolated from
about 80% of the patients with AML have elevated
LDL receptor activities and that leukemic cells with
monocytic differentiation (FAB groups M4 and M5)
have the highest values. All patients studied with
chronic myelocytic leukemia in blast crisis had very
high degradation values. Also, in this group, the high-
est value was found in a patient with a myebomonocytic
leukemia. The leukemic cells from two patients with
ALL had low LDL degradation rates, which is in
agreement with the results obtained by Ho et al.5 In
contrast, we found high degradation rates in leukemic
cells isolated from 2 of 3 patients with AUL.
Recently, Chait et al. have presented evidence that
the observed LDL receptor activity in isolated normal
mononuclear cell suspensions mostly reflects the activ-
ity of monocytes and that lymphocytes have a very low
LDL receptor activity.’5 However, it seems highly
unlikely that the high receptor activity in cells isolated
from AML patients was due to the occurrence of
normal monocytes in the isolated cell suspensions. As
estimated from the data of Chait et al.,’5 a 100% pure
suspension of mature monocytes would have a much
lower degradation rate than the highest values for cells
isolated from leukemic patients in the present study.
Furthermore, in most of the AML patients, leukemic
cells dominated in peripheral blood and bone marrow,
and the percentage of mature monocytes was lower
than in mononuclear cell suspensions from healthy
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subjects. Thus, the high LDL receptor activity in cells
isolated from blood and bone marrow samples of
leukemic patients is likely to be due to the presence of
leukemic cells.
Betteridge and coworkers have shown that leukemic
blast cells have an elevated de novo synthesis of sterols
and do not down-regulate sterob synthesis when
exposed to LDL in vitro.’6 The cholesterol content of
leukemic cells is also lower than that of normal white
blood cells.5’6’7 One explanation for this could be that
the beukemic cells use more cholesterol for membrane
synthesis. This could also explain the elevated LDL
receptor activity in leukemic cells. Recently, it has
been reported that the highest values for de novo
synthesis ofcholesterol are found in leukemic cells with
monocytic differentiation,’5 which is in accordance
with our observation that the highest LDL receptor
activities are found in this subgroup.
The pronounced difference in degradation rate
between cells isolated from the peripheral blood and
bone marrow of some leukemic patients might be due,
at least partly, to different degrees of contamination
with normal cells. When leukemic cells are isolated by
centrigfugation on Lymphoprep, normal mononuclear
cells will be obtained together with the leukemic cells.
In cases where the degradation rate for cells isolated
from bone marrow markedly exceeded that for cells
from peripheral blood, the percentage of leukemic cells
was higher in the bone marrow than in the peripheral
blood. Previously, it has been shown that cultured cells
in the exponential growth phase have higher LDL
receptor activities than resting cells.’92’ Therefore, a
higher LDL receptor activity in leukemic cells from
bone marrow may also be due to the presence of a
higher proportion of dividing cells. This explanation is
supported by results showing a higher level of tritiated
thymidine labeling in leukemic cells from bone marrow
than in cells from peripheral blood.22 Another explana-
tion might be that the leukemic cells in peripheral
blood are exposed to a higher LDL concentration than
cells in the bone marrow. Previous in vitro studies show
that the LDL receptor activity of normal white blood
cells,323 as well as that of leukemic cells,5 can be
enhanced by incubating the cells in a lipoprotein-
deficient medium. However, in a few patients, cells
isolated from peripheral blood had higher LDL recep-
tor activity than cells isolated from bone marrow.
The enhanced LDL receptor activity in leukemic
cells might be of interest for the treatment of patients.
LDL could be used as a vehicle to target cytotoxic
drugs to leukemic cells with a high LDL receptor
activity. Studies by Krieger et al.24 have shown that it
is possible to replace the cholesterol esters in the core of
the LDL particles by exogenous bipophilic substances.
By incorporating the lipophilic cytotoxic agent N-
trifluoroacetyladriamycin- I 4-valerate into LDL, we
have been able to show LDL receptor-mediated drug
uptake in white blood cells in vitro.23 The LDL recep-
tor activities of normal stem and blast cells in the bone
marrow are of critical importance for this approach. It
cannot be excluded from the present study that normal
stem cells and/or blast cells also have high LDL
receptor activities. When isolating nucleated cells from
a normal bone marrow suspension on Lymphoprep,
normal stem and blast cells accumulate together with
lymphocytes, monocytes, red cell precursors, and other
cells at the interface. However, the immature cells
constitute only a very small percentage of the total
number of cells. The observation that not only AML
cells but also normal myeboid progenitor cells have
lower cellular cholesterol contents than mature granu-
bocytes’7 could indicate that normal immature cells
have high LDL receptor activity. However, in our
study, the most immature cells studied from AML
patients classified as FAB-M I had much lower recep-
tor activities than more differentiated cells from
patients classified as M4 and MS.
Another objection that can be raised against the
possibility of using LDL as a drug carrier is the
competition due to the presence of endogenous LDL.
However, our study shows that most patients with
AML have very low plasma cholesterol concentrations
at the time of diagnosis. The finding of a negative
correlation between the LDL receptor activities of the
isolated leukemic cells and the plasma cholesterol
levels of the AML patients indicates that the low
cholesterol levels might be due to elevated receptor-
mediated catabolism of LDL in the body caused by the
presence of leukemic cells. Ginsberg et al. have shown
that patients with polycythemia vera and myeloid
metaplasia have reduced total plasma cholesterol and
LDL cholesterol levels and an increased LDL catabo-
lism.25 They have also reported data that could indicate
both an enhanced receptor-mediated and non-recep-
tor-mediated catabolism of LDL, as estimated from
the clearance of native and chemically modified LDL
in these patients.26
Studies are now in progress to further investigate the
possibility of using LDL as a carrier for cytotoxic
drugs.
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